Premium
Erythrocyte‐Derived Nanoparticles as a Theranostic Agent for Near‐Infrared Fluorescence Imaging and Thrombolysis of Blood Clots
Author(s) -
Vankayala Raviraj,
Corber Samantha R.,
Mac Jenny T.,
Rao Masaru P.,
Shafie Mohammad,
Anvari Bahman
Publication year - 2018
Publication title -
macromolecular bioscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 105
eISSN - 1616-5195
pISSN - 1616-5187
DOI - 10.1002/mabi.201700379
Subject(s) - indocyanine green , thrombolysis , tissue plasminogen activator , fluorescence lifetime imaging microscopy , imaging agent , medicine , stroke (engine) , ischemic stroke , biomedical engineering , pharmacology , chemistry , fluorescence , ischemia , surgery , myocardial infarction , mechanical engineering , physics , microbiology and biotechnology , quantum mechanics , in vivo , engineering , biology
Ischemic stroke occurs when a blood clot obstructs or narrows the arteries that supply blood to the brain. Currently, tissue plasminogen activator (tPA), a thrombolytic agent, is the only United States Food and Drug Administration (FDA)‐approved pharmacologic treatment for ischemic stroke. Despite its effective usage, the major limitation of tPA that stems from its short half‐life in plasma (≈5 min) is the potential for increased risk of hemorrhagic complications. To circumvent these limitations, herein, the first proof‐of‐principle demonstration of a theranostic nanoconstruct system derived from erythrocytes doped with the FDA‐approved near‐infrared (NIR) imaging agent, indocyanine green, and surface‐functionalized with tPA is reported. Using a clot model, the dual functionality of these nanoconstructs in NIR fluorescence imaging and clot lysis is demonstrated. These biomimetic theranostic nanoconstructs may ultimately be effective in imaging and treatment of blood clots involved in ischemic stroke.